H. Asghari

Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia

J. Lancet, H. Asghari, 2020, Leukemia & lymphoma.

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

A. Mishra, J. Lancet, E. Padron, 2019, Blood.

Acute Myeloid Leukemia: Epidemiology and Etiology

K. Sweet, H. Asghari, 2020, Acute Leukemias.

Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.

Chetasi Talati, H. Asghari, 2020, Current opinion in hematology.

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

J. Lancet, E. Padron, H. Fernandez, 2019, Blood.

Acute Leukemias

E. Estey, H. Kantarjian, M. Dreyling, 2021, Handbook of Pediatric Hematology and Oncology.

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

J. Lancet, E. Padron, H. Fernandez, 2019, Blood.

Acute Leukemias

E. Estey, H. Kantarjian, M. Dreyling, 2021, Handbook of Pediatric Hematology and Oncology.